Abstract

Background: Depression is common, disabling, and undertreated. Artificial intelligence (AI) could extend access to psychoeducation, structured self-management, symptom monitoring, and selected clinical decision-support functions. However, claims that AI can diagnose or treat depression frequently outpace the validation of specific systems. Aim: To critically integrate psychological theory, clinical trials, contemporary reviews, and implementation considerations into an actionable, safety-conscious framework for professionals and adults experiencing depressive symptoms. Approach: This critical narrative synthesis draws on landmark psychological models, contemporary randomized studies and meta-analyses, digital-phenotyping reviews, and treatment guidance. It is not a systematic review, and no pooled analysis was conducted. Findings: Conversational interventions yield small average reductions in depressive symptoms across heterogeneous studies. A 2026 synthesis identified 39 eligible studies, of which 38 trials (7,401 participants) contributed to its depression analysis estimated Hedges’ g = 0.31 (95% CI 0.17–0.46). These findings apply to evaluated interventions, not indiscriminately to general-purpose language models. Passive sensing is associated with depressive states, but missing data, confounding, and limited external validation restrict clinical applications. Individualized treatment selection remains investigational. Practice implications: AI appears most defensible as a transparent, opt-in aid to behavioral activation, cognitive exercises, between-session support, and clinician-reviewed measurement-based care. Diagnosis, differential assessment, medication management, and suicide risk evaluation must retain qualified human responsibility. Conclusion: The clinically relevant question is not whether AI can mimic a therapist, but whether a specific AI-enabled workflow improves patient outcomes and access without adding unacceptable risk. Such a claim requires prospective comparative evaluation, equity assessment, accountable oversight, and ongoing monitoring.

1. Introduction: from technological possibility to clinically justified use

The World Health Organization estimates that approximately 322 million people worldwide live with depression, with a substantial treatment gap even in high-income countries (World Health Organization [WHO], 2026). Depression encompasses disturbances of affect, motivation, attention, sleep, appetite, self-evaluation, and functioning; these features vary markedly across individuals. Effective care includes evidence-based psychological therapies, pharmacotherapy where indicated, collaborative follow-up, social interventions, and attention to comorbid illness and material adversity (National Institute for Health and Care Excellence [NICE], 2022).

AI introduces several distinct possibilities: automated dialogue that guides an exercise; statistical tools that identify patterns in repeated assessments; passive sensing that estimates activity or sleep regularity; and predictive models that assist clinical planning. These are not interchangeable technologies. A scripted cognitive behavioral therapy (CBT) intervention, a retrieval-grounded therapy coach, an unrestricted large language model (LLM), and a machine-learning treatment predictor differ in mechanism, testing, failure modes, and regulatory status. Accordingly, the unit of clinical evaluation should be the particular intervention and workflow, not “AI” as a general category.

This article advances three claims. First, AI plausibly helps when it increases the dose, timeliness, or accessibility of established therapeutic processes, particularly behavioral activation and structured reflection. Second, those gains are conditional: engagement, clinical severity, social circumstances, data quality, and escalation pathways determine whether technological availability becomes useful care. Third, safety, effectiveness, equity, and accountability are clinical outcomes, not afterthoughts. The ensuing sections separate evidence from plausible mechanisms and provide operational tools for practice.

2. Conceptual model: what would cause improvement?

2.1 Cognitive theory and guided restructuring

Beck’s cognitive model links depressive persistence to negative beliefs and systematic interpretive biases concerning self, world, and future (Beck et al., 1979). An AI application could help a patient identify an automatic thought, examine evidence, generate a more balanced interpretation, and test predictions behaviorally. For example, “Nobody wants to hear from me” becomes a testable hypothesis rather than an accepted fact. Importantly, fluent restatement of CBT terminology is not proof of competent therapy. A helpful tool must avoid reflexive reassurance, challenge harmful assumptions with sensitivity, and know when contextual information is insufficient.

2.2 Behavioral activation and the reward–avoidance cycle

Behavioral activation conceptualizes withdrawal, avoidance, and reduced contact with reinforcement as important maintaining processes (Dimidjian et al., 2006). AI is well suited to low-friction tasks: jointly choosing a feasible activity, scheduling it, recording pleasure or mastery afterward, identifying obstacles, and adjusting plans. This mechanism has greater face validity than generic motivational conversation because it is tied to an observable behavioral target. The proposed pathway is: specific activity plan → greater behavioral engagement → increased opportunity for reward or mastery → potentially improved mood and functioning. The arrows are hypotheses to evaluate for an individual, not guaranteed effects.

2.3 Stress vulnerability, interpersonal context, and self-determination

Diathesis–stress thinking explains why similar stressors may have different effects across people, while interpersonal approaches emphasize loss, conflict, isolation, and role transitions. Self-determination theory highlights autonomy, competence, and relatedness (Ryan & Deci, 2000). These models yield an important design principle: digital support should reinforce the individual’s agency and actual relationships, rather than encourage dependence on the system. A conversation tool that prompts offline contact and a manageable task may be more therapeutic than one that maximizes time spent chatting. Financial insecurity, discrimination, housing instability, and isolation cannot be “reframed away”; AI responses must recognize where practical, social, or professional assistance is needed.

2.4 A mechanism-to-function framework

3. What the clinical evidence actually shows

3.1 Symptom improvement in conversational interventions

The evidence base has expanded but remains heterogeneous. A 2023 meta-analysis of conversational-agent interventions reported a short-term depression effect of Hedges’ g = 0.29 (95% CI 0.20–0.38), with variation in design and risk of bias. A 2026 meta-analysis by Sohn and colleagues identified 39 eligible studies, of which 38 trials (n = 7,401) contributed to the pooled depression estimate (g = 0.31, 95% CI 0.17–0.46). Notably, 35 of the 39 included studies were judged at high overall risk of bias, and depression-outcome heterogeneity was substantial (I² = 85.34%). Although sign conventions differ, these estimates generally indicate small average benefits over controls. Their different inclusion criteria, comparator conditions, ages, and intervention types mean their estimates cannot simply be averaged or treated as independent replication of one product.

In younger populations, Feng and colleagues (2025) reported a larger pooled reduction in depressive symptoms after adjustment for publication bias (g = 0.61, 95% CI 0.35–0.86), but the review also reported notable heterogeneity and limited follow-up. The larger effect is not evidence that any consumer chatbot works particularly well for adolescents or that risks are adequately characterized.

A notable generative-model trial, the 2025 Therabot study, randomized 210 adults with clinically significant symptoms or elevated risk across depression, generalized anxiety, or eating-disorder groups to a four-week intervention or waitlist. Its carefully designed and monitored research setting offers proof of feasibility and efficacy signals, not evidence that unrestricted LLM conversations are equivalent to clinician-delivered psychotherapy. Waitlist comparisons can exaggerate relative benefits compared with active, credible treatments, and small subgroups restrict certainty about particular diagnoses (Heinz et al., 2025).

Interpretation: A demonstrated reduction in average symptom-score differences should not be confused with remission, restored functioning, durable recovery, noninferiority to human therapy, or safety in crisis. The most defensible immediate use is as a complement to established treatment or a structured lower-intensity support option with appropriate assessment and follow-up.

3.2 Digital phenotyping: promising signal, uncertain actionability

Passive smartphone and wearable data can reflect changes in mobility, circadian patterns, sleep, and device use. Yet patterns are context dependent: limited travel may reflect disability, finances, work-from-home arrangements, culture, or preference rather than depression. Leaning et al. (2024), reviewing 24 studies and 9,801 participants, reported moderate predictive performance, substantial missing-data problems, and limited independent external validation. Reviews published in 2025–2026 likewise document heterogeneity in device platforms, features, sampling, and study settings. For these reasons, a person should not be labelled depressed, or subjected to unsolicited outreach, solely on the basis of passive behavioral signals.

An ethically acceptable experimental workflow would use explicit consent; collect only essential features; report uncertainty and data missingness; compare the individual against their own baseline where appropriate; and present any signal as a prompt for a human conversation rather than a diagnosis. Clinical benefit must be shown by demonstrating that the resulting action improves outcomes beyond repeated validated questionnaires and usual care.

3.3 Prediction of medication response: not yet a prescribing engine

AI models may integrate baseline symptoms and clinical histories to estimate treatment response. In a 2025 medication-selection study, a model trained on trial data from 9,042 adults yielded a held-out area under the receiver-operating-characteristic curve of approximately 0.65 (Aifred investigators, 2025). This is a research signal with limited discrimination, not proof that clinicians should defer to algorithmic antidepressant rankings. Prescribing requires consideration of patient preference, adverse effects, bipolar risk, interactions, comorbidities, affordability, previous experience, and clinical monitoring. Prospective randomized testing of AI-assisted decisions against high-quality measurement-based care is needed before asserting routine clinical advantage.

4. Patient selection, clinical scope, and red flags

For an adult with mild depressive symptoms and preserved safety, an evaluated digital program may be offered as one option for self-management, ideally with a trained practitioner reviewing progress. NICE recommends structured guided self-help approaches for less severe depression, with support and regular reviews; these recommendations do not constitute endorsement of untested AI chatbots (NICE, 2022).

For moderate or severe symptoms, marked functional impairment, recurrent depression, psychotic features, possible mania/hypomania, severe substance misuse, pregnancy-related complexity, or significant physical illness, formal assessment and individualized professional care are important. Structured AI exercises may still be used as adjuncts if the treatment team judges them appropriate. Diagnosis must consider bipolar disorder, bereavement, medication effects, sleep disorders, endocrine conditions, and other potential causes.

Urgent exception: An AI program should never be the sole response to suicidal intent, immediate self-harm risk, psychosis with danger, or inability to care for basic needs. A prompt that suggests emergency care is not equivalent to a successful handoff. Systems need context-appropriate escalation procedures and explicit disclosures that conversations may not be monitored in real time. People in immediate danger should contact local emergency services. In the United States, 988 provides crisis support; availability and appropriate numbers differ by country.

5. An actionable protocol for clinicians

Step 1—Assess before recommending: Establish diagnosis or working formulation, severity, functioning, suicide risk, bipolar symptoms, comorbidity, current treatments, technology access, language, and preferences. A PHQ-9 score is a symptom measure, not a diagnostic substitute; directly follow up any indication of self-harm. Document whether the digital tool is approved or validated for its exact intended use.

Step 2—Choose the narrowest useful function: Prefer a validated, structured intervention for one clear need: behavioral activation homework, CBT thought records, psychoeducation, between-session reminders, or symptom tracking. Avoid unnecessarily broad, anthropomorphic “AI therapist” claims. If a general-purpose chatbot is used for nonsensitive drafting or reflection, describe it as unvalidated for treating depression.

Step 3—Agree on consent and safeguards: Explain that AI can be wrong and may not be private at the level patients expect. Clarify who sees entries, whether conversations train future models, data retention/deletion, identifiable-data restrictions, human review, and procedures if the application detects concerning language. Do not enter identifiable patient information into an unapproved service.

Step 4—Create a shared plan: Specify one or two measurable goals (for example, completing three personally meaningful activities per week, or tracking a daily sleep–wake routine). Define frequency of use, maximum burden, follow-up date, and what counts as worsening. Introduce a clear non-AI route for contacting the team.

Step 5—Measure and reassess: Use a validated symptom instrument such as the PHQ-9 alongside functioning, side effects, patient-defined goals, and therapeutic engagement. A change of about five PHQ-9 points has been used as one clinically interpretable benchmark (Löwe et al., 2004), but response thresholds vary across baselines and settings. Look for meaningful change, not a chatbot’s self-reported success. Review the first two to four weeks and periodically thereafter; the appropriate timing depends on severity and treatment plan.

Step 6—Escalate or discontinue when indicated: Reassess clinically if symptoms worsen, the patient withdraws from human contact, repeated interactions increase rumination, advice conflicts with treatment, or there are new safety concerns. Document decisions, errors, and adverse events. AI should support care coordination, not obscure who is responsible for it.

Compact clinical audit checklist

Before adoption ask: (1) Was the exact version tested in people resembling my patients? (2) Against what comparator and with what follow-up? (3) Were harms and dropouts collected? (4) Is safety escalation operational and tested? (5) Can the patient opt out without losing access to care? (6) Can we monitor outcomes and subgroup disparities? (7) Is the organization willing to withdraw the tool if benefits fail to materialize?

6. A practical guide for adults experiencing depressive symptoms

AI may be useful as a workbook companion, not a clinician, diagnostician, or emergency service. If sadness, loss of interest, low energy, hopelessness, or impaired functioning persist for two weeks or interfere with daily life, consider speaking with a qualified healthcare professional. Early help is especially important if symptoms are severe, recurrent, or worsening.

A five-part, low-burden routine can be implemented with a paper notebook, a validated app, or a cautious AI assistant: (1) Rate mood and energy briefly once daily without obsessively checking scores. (2) Identify one concrete action that matters today, even if very small. (3) Plan when and where to do it, plus a fallback. (4) Afterward, note what happened rather than judging success by immediate happiness. (5) Bring the record to a clinician or trusted support person if symptoms persist or worsen.

For example, instead of asking an AI to “cure my depression,” a safer request is: “Help me choose one achievable activity for today, ask what might get in the way, and help me make a backup plan. Do not diagnose me or advise medication changes.” For cognitive reflection: “Help me write a CBT thought record, separating the situation, automatic thought, evidence for and against it, and an alternative balanced interpretation. Ask clarifying questions rather than assuming facts.” Such prompts organize existing therapeutic techniques; they are not a validated treatment by themselves.

Privacy should be a deliberate choice. Avoid entering full names, addresses, insurance information, medical record numbers, highly sensitive trauma details, or information about other people into services whose data practices are unclear. Check whether a service stores conversations, permits deletion, and allows human review. It is reasonable to stop using a chatbot if it makes you feel worse, encourages isolation or dependency, gives contradictory medical advice, or repeatedly agrees with harmful beliefs.

A useful practical rule is AI for preparation, professionals for diagnosis and treatment decisions, and people for connection. AI can help prepare questions for an appointment, summarize a personal symptom diary, or rehearse how to tell a trusted person that help is needed. It cannot establish whether a medication should be started or stopped, determine imminent suicide risk reliably, or replace a human support network.

7. Clinical governance, regulatory boundaries, and equity

Generative systems can confabulate, be excessively agreeable, mishandle ambiguous disclosures, and respond inconsistently as models are updated. Their output depends on prompts, prior conversation, and safety settings. These are consequential limitations in depression, where hopelessness, self-criticism, psychosis, and self-harm concerns may require sensitive and decisive intervention. Independent research published in 2026 also highlighted disagreement among professionals asked to judge whether mental-health chatbot responses were safe, underscoring the difficulty of relying on simple expert-rating averages (Stanford University, 2026).

Privacy safeguards should include data minimization, encryption where applicable, restricted access, explicit consent, retention limits, audit trails, and meaningful deletion pathways. Passive sensing should be optional rather than a prerequisite to receiving mental healthcare. Clinicians and institutions should evaluate language, disability accommodations, digital literacy, internet access, and model performance in underrepresented groups. Average overall accuracy can conceal systematic mistakes in vulnerable populations.

Regulatory obligations depend on functionality and jurisdiction. The U.S. Food and Drug Administration issued final Clinical Decision Support Software guidance in January 2026; whether software meets a device definition is use-specific, and a wellness label does not automatically exempt clinical claims. Health institutions should obtain current regulatory, privacy, procurement, and professional advice. A published trial of one product does not validate every model version or subsequent upgrade.

8. Research agenda: prove meaningful incremental benefit

The next generation of studies should ask whether AI adds benefit over credible alternatives, not merely whether it outperforms no intervention. Four designs are especially valuable. First, pragmatic randomized trials should compare clinician-guided digital therapy plus usual care against equally accessible, non-AI guided self-help and usual care. Second, dismantling designs should test whether conversational flexibility itself adds value over a structured program. Third, longitudinal designs should evaluate relapse, functioning, care utilization, and adverse events over six to twelve months, not only immediate symptom scores. Fourth, multisite implementation studies should compare equity, workflow burden, alert fatigue, and cost-effectiveness under real clinical conditions.

Trials should preregister primary outcomes, capture attrition, use intention-to-treat analyses, report confidence intervals and clinically meaningful endpoints, and document model/version changes. For triage or passive sensing, externally validated calibration, false-positive/false-negative consequences, and performance by subgroup matter more than internal classification accuracy. Safety evaluation should include standardized challenging scenarios as well as real-world incident review, with explicit escalation outcomes. Patient and clinician co-design can identify otherwise overlooked harms such as privacy anxiety, pressure to disclose, guilt after missed tasks, or displacement of human contact.

9. Conclusion

AI can extend selected therapeutic processes that already have a defensible psychological and clinical foundation. The most compelling near-term applications are structured behavioral activation, CBT-related exercises, low-burden measurement, care navigation, and clinician-reviewed decision support. Meta-analyses support modest average improvements in depressive symptoms for evaluated conversational interventions; they do not establish a general license for AI to diagnose depression, independently manage high-risk patients, or replace skilled psychotherapy. Progress should therefore be judged by improvements in functioning, symptom burden, access, safety, equity, and patient autonomy—not by conversational fluency or engagement time. A trustworthy model of AI-assisted depression care is specific in purpose, limited in claims, accountable to human clinical judgment, and continuously evaluated.

References

Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979). *Cognitive therapy of depression*. Guilford Press.

Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., Gallop, R., McGlinchey, J. B., Markley, D. K., Gollan, J. K., Atkins, D. C., Dunner, D. L., & Jacobson, N. S. (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *Journal of Consulting and Clinical Psychology, 74*(4), 658–670. https://doi.org/10.1037/0022-006X.74.4.658

Feng, Y., Hang, Y., Wu, W., Song, X., Xiao, X., Dong, F., & Qiao, Z. (2025). Effectiveness of AI-driven conversational agents in improving mental health among young people: Systematic review and meta-analysis. *Journal of Medical Internet Research, 27*, e69639. https://doi.org/10.2196/69639

Heinz, M. V., Mackin, D. M., Trudeau, B. M., Bhattacharya, S., Wang, Y., Banta, H. A., Jewett, A. D., Salzhauer, A. J., Griffin, T. Z., & Jacobson, N. C. (2025). Randomized trial of a generative AI chatbot for mental health treatment. NEJM AI, 2(4). https://doi.org/10.1056/AIoa2400802

Leaning, I. E., Ikani, N., Savage, H. S., Leow, A., Beckmann, C., Ruhé, H. G., & Marquand, A. F. (2024). From smartphone data to clinically relevant predictions: A systematic review of digital phenotyping methods in depression. *Neuroscience & Biobehavioral Reviews, 158*, 105541. https://doi.org/10.1016/j.neubiorev.2024.105541

Löwe, B., Unützer, J., Callahan, C. M., Perkins, A. J., & Kroenke, K. (2004). Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. *Medical Care, 42*(12), 1194–1201. https://pubmed.ncbi.nlm.nih.gov/15550799/

National Institute for Health and Care Excellence. (2022). *Depression in adults: Treatment and management* (NICE Guideline NG222). https://www.nice.org.uk/guidance/ng222

Ryan, R. M., & Deci, E. L. (2000). Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. *American Psychologist, 55*(1), 68–78. https://doi.org/10.1037/0003-066X.55.1.68

Sohn, J.-S., Ha, B.-G., Park, S., Kim, J.-J., Lee, E., Oh, H., Lee, S., & Kim, E. (2026). Systematic review and meta analysis of chatbots in the management of depressive and anxiety symptoms. *npj Digital Medicine, 9*, Article 377. https://doi.org/10.1038/s41746-026-02566-w

U.S. Food and Drug Administration. (2026). Clinical decision support software: Guidance for industry and Food and Drug Administration staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software

World Health Organization. (2026, September 11). Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression

Submission disclosures and limitations

This is a critical narrative review, not a systematic review or meta-analysis; it does not claim an exhaustive reproducible search, PRISMA selection procedure, or independent formal study-level risk-of-bias adjudication. Before submission, authors should (a) spot-check all remaining references against original publications, (b) complete a reproducible search-date/database description if required by the selected journal, (c) confirm figures and claims against primary articles, (d) report conflicts of interest, funding, and any generative-AI writing assistance under journal policy, and (e) adapt headings, reference format, length, and permissions to the target journal. The clinical workflow is a proposed synthesis, not a prospectively validated protocol.